Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)

Arch Dis Child Fetal Neonatal Ed. 2021 Mar;106(2):211-214. doi: 10.1136/archdischild-2020-319792. Epub 2020 Oct 6.

Abstract

Background: Less-invasive surfactant administration (LISA) is increasingly used. We investigated the feasibility of a new LISA-device (Neofact®) in neonates.

Design: Prospective observational pilot study with open-label LISA in two tertiary neonatal intensive care units.

Patients: 20 infants with a gestational age of ≥26+0/7 weeks and an indication for LISA (Respiratory Severity Score (RSS)≥5 or fraction of inspired oxygen (FiO2) ≥0.30). Infants with respiratory tract malformations or unavailability of an instructed neonatologist were excluded.

Main outcome measures: Success of LISA, defined as laryngoscopy-confirmed intratracheal catheter position or a decrease in FiO2 by ≥0.05 or to 0.21, accompanied by an RSS decrease of ≥2; number of attempts needed for tracheal catheterisation.

Results: 20/57 screened infants were enrolled. Successful application occurred in 19/20 (95%). One application failed after three attempts. No device-related adverse events occurred. The median number of attempts was 2, success rate per attempt 19/31 (61%).

Conclusion: LISA via Neofact® appears feasible.

Keywords: neonatology; resuscitation; technology.

Publication types

  • Observational Study

MeSH terms

  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Laryngoscopy
  • Pilot Projects
  • Prospective Studies
  • Pulmonary Surfactants / administration & dosage*
  • Pulmonary Surfactants / therapeutic use
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Tertiary Care Centers

Substances

  • Pulmonary Surfactants